Graybug Vision, Inc. Logo

Graybug Vision, Inc.

GRAY

(1.2)
Stock Price

5,50 USD

-127.25% ROA

0% ROE

-1546x PER

Market Cap.

120.983.500,00 USD

0% DER

0% Yield

0% NPM

Graybug Vision, Inc. Stock Analysis

Graybug Vision, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Graybug Vision, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.21x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

4 ROE

The stock's ROE indicates a negative return (-101.78%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-109.56%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-3) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Graybug Vision, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Graybug Vision, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Buy
4 Stoch RSI Sell

Graybug Vision, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Graybug Vision, Inc. Revenue
Year Revenue Growth
2018 0
2019 0 0%
2020 0 0%
2021 0 0%
2022 2.963.000 100%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Graybug Vision, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2018 22.971.000
2019 30.580.000 24.88%
2020 20.962.000 -45.88%
2021 18.903.000 -10.89%
2022 14.113.000 -33.94%
2023 11.088.000 -27.28%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Graybug Vision, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 5.599.000
2019 6.922.000 19.11%
2020 8.870.000 21.96%
2021 17.044.000 47.96%
2022 19.104.000 10.78%
2023 8.244.000 -131.73%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Graybug Vision, Inc. EBITDA
Year EBITDA Growth
2018 -28.203.000
2019 -37.199.000 24.18%
2020 -29.832.000 -24.69%
2021 -35.947.000 17.01%
2022 -29.916.000 -20.16%
2023 -19.332.000 -54.75%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Graybug Vision, Inc. Gross Profit
Year Gross Profit Growth
2018 0
2019 0 0%
2020 0 0%
2021 0 0%
2022 2.963.000 100%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Graybug Vision, Inc. Net Profit
Year Net Profit Growth
2018 -28.378.000
2019 -36.644.000 22.56%
2020 -26.993.000 -35.75%
2021 -33.824.000 20.2%
2022 -35.030.000 3.44%
2023 0 0%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Graybug Vision, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 -2
2019 -35 94.29%
2020 -57 38.6%
2021 -22 -159.09%
2022 -320 93.1%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Graybug Vision, Inc. Free Cashflow
Year Free Cashflow Growth
2018 -29.677.000
2019 -31.820.000 6.73%
2020 -33.087.000 3.83%
2021 -31.988.000 -3.44%
2022 -25.131.000 -27.29%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Graybug Vision, Inc. Operating Cashflow
Year Operating Cashflow Growth
2018 -28.216.000
2019 -31.215.000 9.61%
2020 -32.064.000 2.65%
2021 -31.500.000 -1.79%
2022 -22.879.000 -37.68%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Graybug Vision, Inc. Capital Expenditure
Year Capital Expenditure Growth
2018 1.461.000
2019 605.000 -141.49%
2020 1.023.000 40.86%
2021 488.000 -109.63%
2022 2.252.000 78.33%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Graybug Vision, Inc. Equity
Year Equity Growth
2018 12.019.000
2019 28.409.000 57.69%
2020 94.786.000 70.03%
2021 65.023.000 -45.77%
2022 35.971.000 -80.77%
2023 12.159.000 -195.84%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Graybug Vision, Inc. Assets
Year Assets Growth
2018 17.813.000
2019 40.660.000 56.19%
2020 101.794.000 60.06%
2021 69.088.000 -47.34%
2022 39.670.000 -74.16%
2023 15.845.000 -150.36%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Graybug Vision, Inc. Liabilities
Year Liabilities Growth
2018 5.794.000
2019 12.251.000 52.71%
2020 7.008.000 -74.81%
2021 4.065.000 -72.4%
2022 3.699.000 -9.89%
2023 3.686.000 -0.35%

Graybug Vision, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-1546x
Price To Sales Ratio
40.83x
POCF Ratio
-2989.1
PFCF Ratio
-11.6
Price to Book Ratio
2563.56
EV to Sales
36.9
EV Over EBITDA
-2.51
EV to Operating CashFlow
-10.49
EV to FreeCashFlow
-10.49
Earnings Yield
-0
FreeCashFlow Yield
-0.09
Market Cap
0,12 Bil.
Enterprise Value
0,11 Bil.
Graham Number
0.01
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.39
ROE
-0.93
Return On Assets
0
Return On Capital Employed
-0.94
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
9.15
Research & Developement to Revenue
4.67
Stock Based Compensation to Revenue
4.34
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-2.58
Return on Tangible Assets
-1.27
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
-0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.27
Current Ratio
4.14
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
0
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Graybug Vision, Inc. Dividends
Year Dividends Growth

Graybug Vision, Inc. Profile

About Graybug Vision, Inc.

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

CEO
Dr. Frederic Guerard Pharm.D.
Employee
8
Address
203 Redwood Shores Parkway
Redwood City, 94065

Graybug Vision, Inc. Executives & BODs

Graybug Vision, Inc. Executives & BODs
# Name Age
1 Dr. Parisa Zamiri M.D., Ph.D.
Chief Medical Officer
70
2 Mr. Ming Yang
Senior Vice President of R&D
70
3 Dr. Frederic Guerard Pharm.D.
Pres, Chief Executive Officer, Sec. & Director
70
4 Mr. Robert S. Breuil
Chief Financial Officer & Treasurer
70
5 Dr. Ward M. Peterson Ph.D.
Senior Vice President of Preclinical Devel.
70
6 Mr. Ali Kakavand Ph.D.
Vice President & Head of Program Management
70
7 Dr. Peter A. Campochiaro M.D.
Co-Founder
70
8 Dr. Peter J. McDonnell M.D.
Co-Founder
70
9 Dr. Gerald D. Cagle Ph.D.
Senior Advisor & Head of Bus. Devel.
70
10 Ms. Bettina Maunz
Chief People Officer & Head of Communications
70
11 Ms. Han Wettenstein
Vice President & Controller
70

Graybug Vision, Inc. Competitors